Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Akums Drugs & Pharmaceuticals Ltd. is a leading manufacturer of generic and specialty pharmaceuticals, with a strong presence in the Indian market and exports to over 100 countries. The company differentiates itself through its extensive product portfolio, including over 300 formulations across various therapeutic segments, and a robust manufacturing capacity with 14 facilities certified by global regulatory bodies.
Akums generates revenue primarily through the sale of generic drugs, leveraging its cost-effective manufacturing processes and economies of scale. The company benefits from strong pricing power in the generic segment due to its extensive product range and established relationships with healthcare providers.
Regulatory approvals for new drug formulations
Changes in pricing regulations in key markets like India and the US
Expansion of export markets, particularly in Europe and North America
New partnerships or contracts in contract manufacturing
Regulatory changes affecting drug pricing and approval processes
Technological disruption in drug manufacturing processes
Intensifying competition from both domestic and international generic drug manufacturers
Potential for price erosion in key therapeutic areas
Low liquidity risk due to a current ratio of 3.25
Potential risks associated with foreign exchange fluctuations from international sales
moderate - The pharmaceutical sector generally exhibits resilience during economic downturns, but demand for non-essential medications may decline.
Interest rates affect Akums primarily through the cost of financing for capital expenditures, which are low given the company's debt/equity ratio of 0.05. Higher rates could also impact consumer spending on healthcare products.
minimal - The company has a low debt level, reducing its exposure to credit conditions.
growth - Investors are likely attracted to Akums due to its strong revenue growth potential in the generic pharmaceutical market.
moderate - The stock has shown a 1-year return of 4.9%, indicating relatively stable performance.